Author: Capwell Communications

JASMINE Trial Demonstrates Prolacta’s Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan’s Renowned Low NEC Rate

April 30, 2026
Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company’s Integrated Sacral Neuromodulation System for Urinary Urge Incontinence

March 6, 2026

JASMINE Trial Demonstrates Prolacta’s Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan’s Renowned Low NEC Rate